D. Lee

发表

The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results

P. Vyas, C. Takimoto, S. Kambhampati, 2019, Blood.

Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results.

P. Vyas, C. Takimoto, S. Kambhampati, 2020 .

The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results.

P. Vyas, C. Takimoto, S. Kambhampati, 2019, Journal of Clinical Oncology.

Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach

J. Zeidner, D. Lee, 2019, Expert opinion on investigational drugs.

A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia

J. Esteve, O. Frankfurt, D. Bearss, 2021, Blood Cancer Journal.

Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia

K. Kolibaba, B. Smith, D. Bearss, 2020, Clinical Cancer Research.

Phase I Study of the PTEFb Inhibitor BAY 1251152 in Patients with Acute Myelogenous Leukemia

M. Frattini, O. Ottmann, M. Wermke, 2018, Blood.

Options After Chemotherapy for Patients with Metastatic, Castration-Resistant Prostate Cancer

N. Shore, D. Lee, 2018 .

AML-196: The First-in-Class Anti-CD47 Antibody Magrolimab in Combination with Azacitidine Is Well Tolerated and Effective in AML Patients: Phase 1b Results

P. Vyas, R. Larson, C. Takimoto, 2021 .

Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia (AML)

M. Konopleva, N. Pemmaraju, M. Frattini, 2022, Blood.